14th September 2021 12:45 - 17:15 (GMT+01:00) Europe/London
Virtual event –Tuesday 14 September 2021 12:45-17:15 BST/GMT+1
Radiobiology has had a pivotal role in the safe delivery of ionising radiation for decades and continues to feed our understanding of both tumour response and normal tissue toxicity for decades. With the advent of greater technological capability to deliver photon dose distributions with both greater conformity and precision (through IMRT, VMAT, IGRT and SRS/SBRT) and also with the availability of other modalities (such as proton beam therapy), changes to dose, fractionation and overall treatment time are now more possible than ever, but still require a solid understanding of both likely tumour response and normal tissue toxicity especially in clinical practice for aspects like treatment interruptions and re-treatment tolerances, especially with respect to experiences during the COVID19 pandemic. Radiobiology has a key voice to contribute to a solid understanding in these discussions and changes, alongside robust clinical trials, in order to deliver such modern treatments with optimum safety and efficacy.
This virtual event brings together world experts in giving a refresher for up-to-date key radiobiological principles underlying conventional and modern, altered delivery patterns; and also for practical experience of its use in treatment interruptions, re-treatment tolerances and radiobiologically optimised treatment planning. It will also be a teaching opportunity for radiobiological understanding for the newer treatments which encompass a change in modality and delivery (e.g. particle therapy and dose rate effects).
The teaching faculty have worldwide expertise in Radiobiological research and understanding in clinical Radiotherapy practice. They are:
The event will also give our sponsors the opportunity to give short talks highlighting how radiobiological models are currently introduced into radiotherapy treatment planning.
Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA currently has over 1,000 employees working across 31 sites in 12 countries (Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US). The company also has global manufacturing capabilities with 19 facilities in eight countries, and six research & development sites. For more information, please visit: https://www.adacap.com/.
Bayer’s Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999 www.radiology.bayer.co.uk
GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.
Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people`s lives across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people`s health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. www.philips.co.uk/healthcare
Siemens Healthineers is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. For more information and latest product line visit www.siemens-healthineers.co.uk